Table 3.
Frequency of HLA-I alleles as KIR ligands in patients with AML compared to controls.
| HLA alleles | AML: 2n = 362 (%) | Control: 2n = 362 (%) | P-value OR (95% CI) |
|---|---|---|---|
| C1 | 180 (49.7) | 176 (48.6) | 0.76 |
| C2 | 182 (50.3) | 186 (51.4) | |
| B Bw4 | 150 (41.4) | 145 (40.1) | 0.70 |
| B Bw6 | 212 (58.6) | 217 (59.9) | |
| n = 181 (%) | n = 181 (%) | ||
| B Bw4Ile80 | 92 (50.8) | 91 (50.3) | 0.91 |
| B Bw4Thr80 | 29 (16.0) | 29 (16.0) | > 0.99 |
| A Bw4 | 50 (27.6) | 70 (38.7) | 0.02 |
| 0.60 (0.38–0.94) | |||
| A*23/24 | 37 (20.4) | 53 (29.3) | 0.051 |
| A*32 | 18 (9.9) | 20 (11.0) | 0.73 |
| Total Bw4 | 134 (74.0) | 136 (75.1) | 0.80 |
| A*03 | 33 (18.2) | 40 (22.1) | 0.35 |
| A*11 | 32 (17.7) | 49 (27.1) | 0.03 |
| 0.57 (0.34–0.95) |
The Chi-square test was done based on a 2 × 2 contingency table, p < 0.05 was considered significant. OR: odds ratio, CI: confidence interval.
Significant values are in bold.